MDA435/LCC6 and MDA435/LCC6MDR1: ascites models of human breast cancer

Leonessa, Fabio; Green, D; Licht, Thomas; Wright, Ann; Wingate-Legette, K; Lippman, Jeremy; Gottesman, M M; Clarke, Robert

doi:10.1038/bjc.1996.29

Cited by 92 publications

(91 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…First, the highest tissue levels of ASO obtained after administration of the unencapsulated form was in the kidney. This is consistent with previous studies [20] and is indicative of rapid renal clearance of this agent. Second, the levels of ASO in the spleen and liver are equivalent on a weight basis and the levels within these tissues are reasonably constant over the 24 h time course.…”

Section: N O T F O R D I S T R I B U T I O Nsupporting

confidence: 82%

“…In addition, the MDA435/LCC6 can grow as an ascitic tumor and was isolated from a metastasis of a MDA-MB-435 cell derived tumor. 20 Initial assessment of VEGF secretion was in supernatants collected from confluent cells grown in tissue culture. This data, shown in Figure 1A, indicates that there was a significant 2.9-fold increase in VEGF levels in the supernatant derived from MDA435/LCC6 cells when compared to levels produced by the parental line.…”

Section: Assessment Of Vegf and Her-2/neu Status In The Mda435/lcc6mentioning

confidence: 99%

“…The development of a human xenograft ascites model fulfilling some of these requirements has been achieved in the MDA435/LCC6 model. 20 This model has a reproducible growth curve in immune compromised mice and exhibits sensitivity to cytotoxic drugs known to be active in the treatment of human breast cancer patients. 20 The cells are easily maintained in vitro, thus allowing rapid assessment of drugs both in vitro and in vivo.…”

Section: Introductionmentioning

confidence: 99%

“…20 This model has a reproducible growth curve in immune compromised mice and exhibits sensitivity to cytotoxic drugs known to be active in the treatment of human breast cancer patients. 20 The cells are easily maintained in vitro, thus allowing rapid assessment of drugs both in vitro and in vivo. In this report we provide a further characterization of the MDA435/LCC6 model for VEGF and HER-2/neu expression.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Pharmacodynamic Behavior of Liposomal Antisense Oligonucleotides Targeting Her-2/neu and Vascular Endothelial Growth Factor in an Ascitic MDA435/LCC6 Human Breast Cancer Model

Waterhouse¹,

Dragowska²,

Gelmon³

et al. 2004

Cancer Biology & Therapy

View full text Add to dashboard Cite

The nature of anti-cancer therapeutics is currently undergoing a paradigm change, with biologic agents slowly being introduced into the therapeutic armory, displacing or complimenting the traditionally used cytotoxic agents. These new agents include monoclonal antibodies, recombinant DNA, antisense oligonucleotides (ASO) and others. To assess the new therapeutics, new predictive models are required. Utilizing the MDA435/LCC6 human breast cancer xenograft model, the pharmacokinetic behavior of antisense oligonucleotides targeted against vascular endothelial growth factor and HER-2/neu was assessed. For pharmacodynamic analysis, ASO in buffer or encapsulated in a liposomal formulation were injected intravenously or intraperitoneally into MDA435/LCC6 ascites tumor-bearing mice. Plasma antisense elimination, tissue distribution, total peritoneal antisense and peritoneal cell associated antisense levels were determined. Liposomal encapsulation led to significant decreases in the plasma elimination rate, as evidenced by an approximate 10-fold increase in mean AUC over 24 hours, as well as enhanced peritoneal cell delivery in mice bearing ascites tumors. Tissue distribution studies of both free and liposome encapsulated ASO indicated that ASO distribution was dictated primarily by the liposomal carrier when administered in liposomal form.

show abstract

Section: N O T F O R D I S T R I B U T I O Nsupporting

confidence: 82%

Section: Assessment Of Vegf and Her-2/neu Status In The Mda435/lcc6mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Pharmacodynamic Behavior of Liposomal Antisense Oligonucleotides Targeting Her-2/neu and Vascular Endothelial Growth Factor in an Ascitic MDA435/LCC6 Human Breast Cancer Model

Waterhouse¹,

Dragowska²,

Gelmon³

et al. 2004

Cancer Biology & Therapy

View full text Add to dashboard Cite

show abstract

“…Solubilized membrane fragments were prepared from the Pgp-positive MDA435/LCC6 MDR1 (Pgp(+)) cell line obtained by transduction of Pgp-negative MDA435/LCC6 breast cancer cells (Pgp(−)) with a retroviral vector carrying MDR1 cDNA (Leonessa et al 1996). Pgp(+)- and Pgp(−)-CMAC columns were prepared by the immobilization of the Pgp(+) and Pgp(−) membranes on the surface of a silica-based liquid chromatography support to create CMAC(Pgp(+)) and CMAC(Pgp(−)) columns (Zhang et al 2000) or within a glass capillary column (Moaddel et al 2006).…”

Section: Determination Of Stereoselective Ligand Interactions With Drmentioning

confidence: 99%

Determination and modelling of stereoselective interactions of ligands with drug transporters: A key dimension in the understanding of drug disposition

et al. 2008

View full text Add to dashboard Cite

Stereochemistry is an important dimension in pharmacology and plays a role in every aspect of the pharmacological fate of chiral xenobiotics. This includes small molecule–drug transporter binding. This paper reviews the reported stereoselectivities of substrate and inhibitor interactions with P-glycoprotein and the organic cation transporter obtained using standard functional and binding studies, as well as data obtained from online cellular membrane affinity chromatography studies. The use of stereochemical data in quantitative structure–activity relationship (QSAR) and pharmacophore modelling is also addressed as is the effect of ignoring the fact that small molecule–drug transporter interactions take place in three-dimensional and asymmetric space.

show abstract

Increased intracellular drug accumulation and complete chemosensitization achieved in multidrug-resistant solid tumors by co-administering valspodar(PSC 833) with sterically stabilized liposomal doxorubicin

2000

View full text Add to dashboard Cite

MDA435/LCC6 and MDA435/LCC6MDR1: ascites models of human breast cancer

Cited by 92 publications

References 29 publications

Pharmacodynamic Behavior of Liposomal Antisense Oligonucleotides Targeting Her-2/neu and Vascular Endothelial Growth Factor in an Ascitic MDA435/LCC6 Human Breast Cancer Model

Pharmacodynamic Behavior of Liposomal Antisense Oligonucleotides Targeting Her-2/neu and Vascular Endothelial Growth Factor in an Ascitic MDA435/LCC6 Human Breast Cancer Model

Determination and modelling of stereoselective interactions of ligands with drug transporters: A key dimension in the understanding of drug disposition

Increased intracellular drug accumulation and complete chemosensitization achieved in multidrug-resistant solid tumors by co-administering valspodar(PSC 833) with sterically stabilized liposomal doxorubicin

Contact Info

Product

Resources

About